SuperworthKorro Bio revenue KRRO
Sales by quarter and over the last twelve months, from 2019.
- Last 12 months, to Jun 30, 2026
- $2.4M
- Latest quarter, Q2 FY26
- $0
- −100% on a year earlier
- Fiscal year 2025
- $6.4M
- +181% on the year before
Korro Bio's revenue was $2.4M over the twelve months to Jun 30, 2026, down 62% on a year earlier.
In its latest quarter, Q2 FY26, it was $0, down 100% on the same quarter a year before.
Revenue over time
Fiscal year by fiscal year
| Fiscal year | Revenue | Change |
|---|---|---|
| FY2025 | $6.4M | +181% |
| FY2024 | $2.3M | n/a |
| FY2022 | $0 | −100% |
| FY2021 | $14.1M | −62% |
| FY2020 | $37M | n/a |
| FY2019 | n/a | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | Revenue | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q2 FY26 | $0 | −100% | $2.4M | |
| Q1 FY26 | $0 | −100% | $3.8M | |
| Q4 FY25 | $1.3M | −43% | $6.4M | |
| Q3 FY25 | $1.1M | n/a | $7.4M | |
| Q2 FY25 | $1.5M | n/a | $6.3M | |
| Q1 FY25 | $2.5M | n/a | $4.8M | |
| Q4 FY24 | $2.3M | n/a | $2.3M | |
| Q3 FY24 | $0 | n/a | n/a | |
| Q2 FY24 | $0 | n/a | n/a | |
| Q1 FY24 | $0 | n/a | n/a | |
| Q4 FY22 | $0 | n/a | $0 | |
| Q3 FY22 | $0 | n/a | $0 |
Against its peers
Companies in Drug Manufacturers - General nearest Korro Bio's size, closest first, today.
| Company | Revenue, 12 months | Growth |
|---|---|---|
| KRROKorro Bio | $2.4M | −62% a year |
| NATRNatures Sunshine Products | $492M | +7% a year |
| LFVNLifevantage | $182.6M | −20% a year |
| ARVNArvinas | $316.7M | −15% a year |
| SPROSpero Therapeutics | $47M | −3% a year |
| PBYIPuma Biotechnology | $231.2M | −3% a year |
| IRWDIronwood Pharmaceuticals | $389.3M | +26% a year |
| ZVRAZevra Therapeutics | $136.1M | +119% a year |
| CRMDCorMedix | $462.2M | +281% a year |
| ATNMActinium Pharmaceuticals | n/m | |
| COLLCollegium Pharmaceutical | $808.2M | +14% a year |
| Peer median | $316.7M |
What the revenue tells you
Total sales in the period. On the company page, quarterly bars or the trailing twelve months (TTM), which smooths seasonality.
Growing revenue with shrinking margins is a warning, not a win.
More on Korro Bio
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.